

Thomas Berg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7182867/thomas-berg-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

327
papers

24,480
citations

72
h-index

150
g-index

356
ext. papers

28,415
ext. citations

6.9
avg, IF

6.51
L-index

#	Paper	IF	Citations
327	Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.. <i>Current Oncology</i> , 2022 , 29, 565-577	2.8	
326	Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation.. <i>JHEP Reports</i> , 2022 , 4, 100418	10.3	
325	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. <i>Pathogens</i> , 2022 , 11, 517	4.5	0
324	Hepatic Hedgehog Signaling Participates in the Crosstalk between Liver and Adipose Tissue in Mice by Regulating FGF21. <i>Cells</i> , 2022 , 11, 1680	7.9	0
323	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 314-320	6.1	8
322	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
321	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , 2021 ,	13.4	5
320	Reply to: "G-CSF in acute-on-chronic liver failure - Art of patient selectionNs paramount!". <i>Journal of Hepatology</i> , 2021 ,	13.4	
319	Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
318	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. <i>Liver International</i> , 2021 , 41, 1518-1522	7.9	1
317	COVID-19 and the liver - Lessons learned. <i>Liver International</i> , 2021 , 41 Suppl 1, 1-8	7.9	8
316	A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021 , 41, 2139-2148	7.9	0
315	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100290	10.3	0
314	Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link?. <i>Hepatology Communications</i> , 2021 , 5, 2151-2152	6	1
313	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
312	Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. <i>Antiviral Research</i> , 2021 , 185, 104992	10.8	10
311	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021 , 72, 202-211	11.6	17

310	Antibacterial effect of a brominated self-etch adhesive on carious dentin - An in vivo study. <i>Journal of Dentistry</i> , 2021 , 105, 103555	4.8	0
309	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , 2021 , 75, 1346-1354	13.4	11
308	The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021 , 75, 474-480	13.4	13
307	Reply to: Correspondence on The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021 , 75, 1499-1501	13.4	
306	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021 , 70, 103521	8.8	5
305	Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN- γ -induced depression. <i>Journal of Affective Disorders</i> , 2021 , 292, 766-772	6.6	2
304	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	17
303	Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 706-711	2.4	4
302	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 1037-1045	13.4	34
301	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 500-512	6.1	3
300	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 610-619	3.4	12
299	The stopping rules in hepatitis B virus therapy: can we provide any guidance? 2020 , 175-181		
298	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020 , 2, 100113	10.3	280
297	Effect of a bioactive cement on the microbial community in carious dentin after selective caries removal - An in-vivo study. <i>Journal of Dentistry</i> , 2020 , 92, 103264	4.8	4
296	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557	13.4	88
295	Evaluation of muscarinic acetylcholine receptor type β gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis. <i>Hepatology Research</i> , 2020 , 50, 321-329	5.1	2
294	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
293	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , 2020 , 2, 100168	10.3	7

292	Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver. <i>Cells</i> , 2020 , 9,	7.9	3
291	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. <i>JHEP Reports</i> , 2020 , 2, 100173	10.3	10
290	Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. <i>Scientific Reports</i> , 2020 , 10, 18345	4.9	7
289	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020 , 2, 100169	10.3	68
288	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020 , 72, 88-102	11.2	46
287	Neue molekulare Marker zum Management von HBV-Infektionen?. <i>Gastro-News</i> , 2019 , 6, 50-57	0	
286	The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1589-1600	5.5	3
285	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4073-4073	2.2	6
284	Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence. <i>Annals of Transplantation</i> , 2019 , 24, 527-531	1.4	4
283	Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1424-1431	2.2	5
282	Hepatitis C Virus (HCV) Infection: in Special Situations 2019 , 470-489		
281	Molecular characterization of intact cell-derived and cell-free bacterial DNA from carious dentine samples. <i>Journal of Microbiological Methods</i> , 2019 , 158, 33-43	2.8	4
280	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
279	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
278	Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. <i>Liver International</i> , 2019 , 39, 263-270	7.9	4
277	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019 , 70, 494-500	13.4	46
276	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018 , 68, 839-847	11.2	46
275	Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients". <i>Journal of Hepatology</i> , 2018 , 68, 1104-1105	13.4	1

274	Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2018 , 38 Suppl 1, 90-96	7.9	23
273	Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 280-283	2.2	1
272	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1475-1483	0.7	50
271	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. <i>United European Gastroenterology Journal</i> , 2018 , 6, 213-224	5.3	16
270	Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?". <i>Journal of Hepatology</i> , 2018 , 68, 611-612	13.4	
269	Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , 2018 , 34, 261-268	2.4	11
268	Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1066-1074	7	38
267	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , 2018 , 35, 843-857	4.7	10
266	Molecular quantification and differentiation of <i>Candida</i> species in biological specimens of patients with liver cirrhosis. <i>PLoS ONE</i> , 2018 , 13, e0197319	3.7	10
265	Potentially inappropriate liver transplantation in the era of the "sickest first" policy - A search for the upper limits. <i>Journal of Hepatology</i> , 2018 , 68, 798-813	13.4	48
264	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy248	1	4
263	Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1271-1281	6.1	17
262	A systematic review and meta-analysis of HCV clearance. <i>Liver International</i> , 2017 , 37, 1431-1445	7.9	24
261	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. <i>Gut</i> , 2017 , 66, 1829-1837	19.2	17
260	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
259	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017 , 153, 113-122	13.3	180
258	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017 , 67, 370-398	13.4	2354
257	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017 , 66, 1444-1453	11.2	180

256	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017 , 67, 237-245	13.4	20
255	Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. <i>PLoS ONE</i> , 2017 , 12, e0174424	3.7	21
254	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. <i>Journal of Hepatology</i> , 2017 , 67, 918-924	13.4	146
253	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017 , 66, 11-18	13.4	41
252	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 187-92 ^{2.2}		2
251	Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure. <i>European Journal of Internal Medicine</i> , 2016 , 36, e37-e39	3.9	7
250	Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 1285-92	2.2	7
249	Reply. <i>Hepatology</i> , 2016 , 63, 1052-3	11.2	
248	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
247	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
246	Clinical Trial Watch: Reports from the Liver Meeting□, AASLD, San Francisco, November 2015. <i>Journal of Hepatology</i> , 2016 , 64, 1428-45	13.4	3
245	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016 , 64, 773-80	13.4	169
244	Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. <i>Annals of Transplantation</i> , 2016 , 21, 368-72	1.4	1
243	Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection. <i>Liver International</i> , 2016 , 36, 1267-74	7.9	21
242	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1882-1887	4	7
241	AscitesNeutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation. <i>Scientific Reports</i> , 2016 , 6, 37926	4.9	7
240	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. <i>Hepatology</i> , 2016 , 63, 418-27	11.2	29
239	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 875-886.e6	6.9	141

238	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015 , 64, 1289-95	19.2	146
237	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 285-294.e1	7.9	4
236	Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. <i>Journal of Hepatology</i> , 2015 , 62, 1256-64	13.4	50
235	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
234	Interferon- λ s12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
233	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. <i>Nature Genetics</i> , 2015 , 47, 1443-8	36.3	303
232	Noninvasive characterization of graft steatosis after liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 224-32	2.4	23
231	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. <i>Hepatology</i> , 2015 , 61, 66-76	11.2	141
230	Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. <i>Hepatology</i> , 2015 , 61, 460-70	11.2	28
229	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , 2015 , 35, 2275-84	7.9	
228	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015 , 121, 3631-8	6.4	125
227	Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. <i>Hepatology</i> , 2015 , 62, 726-36	11.2	3
226	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2015 , 62, 1375-87	11.2	19
225	Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. <i>British Journal of Psychiatry</i> , 2015 , 206, 45-51	5.4	13
224	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. <i>Liver International</i> , 2015 , 35, 448-54	7.9	6
223	Entzündliche Lebererkrankungen 2015 , 303-349		
222	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. <i>Human Molecular Genetics</i> , 2014 , 23, 3883-90	5.6	36
221	Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. <i>Hepatology</i> , 2014 , 59, 49-57	11.2	63

220	Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. <i>Gastroenterology</i> , 2014 , 147, 443-52.e5	13.3	201
219	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. <i>Journal of Hepatology</i> , 2014 , 60, 928-33	13.4	48
218	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , 2014 , 370, 1973-82	59.2	754
217	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. <i>Gastroenterology</i> , 2014 , 146, 430-41.e6	13.3	193
216	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. <i>Journal of Hepatology</i> , 2014 , 61, 1073-9	13.4	28
215	Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 1754-7	9.7	13
214	The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2014 , 46, 903-8	3.3	31
213	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. <i>Gut</i> , 2014 , 63, 207-15.9.2	9.2	26
212	Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. <i>PLoS ONE</i> , 2014 , 9, e91987	3.7	89
211	Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. <i>PLoS ONE</i> , 2014 , 9, e87974	3.7	14
210	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. <i>Hepatology International</i> , 2014 , 8, 517-26	8.8	5
209	Antiviral therapy of chronic hepatitis B. <i>Intervirology</i> , 2014 , 57, 171-80	2.5	11
208	Reply to: "underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients". <i>Journal of Hepatology</i> , 2014 , 61, 1185-6	13.4	3
207	SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α 2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3429-36	5.9	13
206	Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. <i>Zeitschrift Fur Gastroenterologie</i> , 2014 , 52, 1185-1197	1.6	5
205	Reply: To PMID 23929603. <i>Hepatology</i> , 2014 , 60, 1449-50	11.2	
204	Hepcidin as a predictor of treatment response in chronic hepatitis C infection. <i>Hepatology</i> , 2014 , 59, 1648	11.2	4
203	A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. <i>Depression Research and Treatment</i> , 2014 , 2014, 821381	3.8	4

202	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2014 , 60, 715-22	13.4	73
201	PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e94512	3.7	15
200	Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e112592	3.7	17
199	Intrahepatic cholestasis in common chronic liver diseases. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1069-83	4.6	38
198	Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection. <i>Hepatology</i> , 2013 , 57, 416-7	11.2	2
197	Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. <i>Gastroenterology</i> , 2013 , 144, 1116-28	13.3	41
196	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. <i>Journal of Hepatology</i> , 2013 , 58, 452-9	13.4	7
195	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. <i>Digestive and Liver Disease</i> , 2013 , 45, 323-33	9.3	5
194	Treatment of HBV related cirrhosis. <i>Liver International</i> , 2013 , 33 Suppl 1, 176-81	7.9	13
193	Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013 , 27, 195-208	6.5	52
192	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013 , 13, 497-506	25.5	73
191	Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. <i>Journal of Virology</i> , 2013 , 87, 6172-81	6.6	82
190	Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. <i>PLoS ONE</i> , 2013 , 8, e64053	3.7	53
189	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013 , 62, 760-5	19.2	132
188	Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 416-20	2.2	10
187	Escitalopram for the prevention of peginterferon- α -associated depression. <i>Annals of Internal Medicine</i> , 2013 , 158, 140	8	1
186	Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 594-600	2.2	7
185	Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. <i>PLoS ONE</i> , 2013 , 8, e77530	3.7	7

184	Influence of the CXCL1 rs4074 A allele on alcohol induced cirrhosis and HCC in patients of European descent. <i>PLoS ONE</i> , 2013 , 8, e80848	3.7	17
183	The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. <i>Deutsches Arzteblatt International</i> , 2013 , 110, 85-91	2.5	65
182	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. <i>Annals of Hepatology</i> , 2013 , 12, 190-198	3.1	1
181	Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , 2013 , 8, e67481	3.7	10
180	The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. <i>International Journal of Cancer</i> , 2012 , 130, 1470-5	7.5	64
179	Escitalopram for the prevention of peginterferon- α -associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. <i>Annals of Internal Medicine</i> , 2012 , 157, 94-103	8	53
178	Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2012 , 56, 1207-1208	13.4	11
177	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. <i>Journal of Hepatology</i> , 2012 , 56, 520-6	13.4	107
176	The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. <i>Journal of Hepatology</i> , 2012 , 56, 758-64	13.4	11
175	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012 , 56, 1247-53	13.4	92
174	The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. <i>Journal of Clinical Virology</i> , 2012 , 54, 279-81	14.5	29
173	TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. <i>BMC Cancer</i> , 2012 , 12, 85	4.8	20
172	Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. <i>Gastroenterology</i> , 2012 , 143, 439-47.e1	13.3	28
171	A genetic validation study reveals a role of vitamin D metabolism in the response to interferon- α -based therapy of chronic hepatitis C. <i>PLoS ONE</i> , 2012 , 7, e40159	3.7	46
170	High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. <i>PLoS ONE</i> , 2012 , 7, e41206	3.7	36
169	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. <i>Hepatology</i> , 2012 , 55, 1700-10	11.2	70
168	Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. <i>European Radiology</i> , 2012 , 22, 1101-9	8	50
167	Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 1353-61	2.4	24

166	HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. <i>Intervirology</i> , 2012 , 55, 102-7	2.5	27
165	Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 334-8	3	32
164	Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. <i>Antiviral Therapy</i> , 2012 , 17, 1049-58	1.6	14
163	A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. <i>PLoS ONE</i> , 2012 , 7, e29433	3.7	14
162	Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. <i>PLoS ONE</i> , 2012 , 7, e42139	3.7	40
161	Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. <i>Gastroenterology</i> , 2011 , 141, 1656-64	13.3	35
160	Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 1990-9	13.3	95
159	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. <i>Genome Medicine</i> , 2011 , 3, 57	14.4	57
158	A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. <i>Human Immunology</i> , 2011 , 72, 273-7	2.3	8
157	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , 2011 , 54, 227-35	13.4	16
156	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. <i>Journal of Hepatology</i> , 2011 , 54, 415-21	13.4	186
155	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011 , 54, 1114-22	13.4	98
154	Silibinin in hepatitis C related liver transplantation. <i>Journal of Hepatology</i> , 2011 , 54, 592-593	13.4	11
153	Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. <i>Journal of Hepatology</i> , 2011 , 55, 732-733	13.4	29
152	The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5B2 mutation. <i>Journal of Hepatology</i> , 2011 , 55, 1201-6	13.4	20
151	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , 2011 , 54, 1538-46	11.2	43
150	Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 289-96	1.9	29
149	Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. <i>Antiviral Therapy</i> , 2011 , 16, 1021-33	1.6	54

148	Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. <i>Liver International</i> , 2011 , 31, 1574-88	7.9	55
147	The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. <i>Journal of Gastroenterology</i> , 2011 , 46, 1427-36	6.9	21
146	The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?. <i>AIDS Research and Therapy</i> , 2011 , 8, 7	3	9
145	Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. <i>Liver Transplantation</i> , 2011 , 17, 289-98	4.5	57
144	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011 , 53, 62-72	11.2	242
143	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. <i>Hepatology</i> , 2011 , 53, 86-95	11.2	202
142	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011 , 54, 443-51	11.2	132
141	Impact of the MELD allocation after its implementation in liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 941-8	2.4	27
140	Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 1458-67	2.4	87
139	Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1111-4	11.6	3
138	Pregnancy in primary sclerosing cholangitis. <i>Gut</i> , 2011 , 60, 1117-21	19.2	47
137	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. <i>PLoS Medicine</i> , 2011 , 8, e1001092	11.6	93
136	The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. <i>PLoS ONE</i> , 2011 , 6, e27087	3.7	91
135	Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. <i>Clinical Transplantation</i> , 2010 , 24, 652-9	3.8	37
134	Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. <i>Radiology</i> , 2010 , 257, 80-6	20.5	172
133	Management of chronic hepatitis B: status and challenges beyond treatment guidelines. <i>Seminars in Liver Disease</i> , 2010 , 30, 361-77	7.3	33
132	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. <i>Gastroenterology</i> , 2010 , 138, 1338-45, 1345.e1-7	13.3	956
131	Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. <i>Gastroenterology</i> , 2010 , 139, 1207-17	13.3	127

130	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. <i>Trends in Molecular Medicine</i> , 2010 , 16, 277-86	11.5	56
129	HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. <i>Journal of Hepatology</i> , 2010 , 53, 1022-8	13.4	12
128	Quantitative detection and typing of hepatitis D virus in human serum by real-time polymerase chain reaction and melting curve analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010 , 67, 172-9 ^{2.9}		15
127	Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 808-12	2.2	1
126	Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon- α 2a and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1303-7	2.2	22
125	Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2063-9	4	20
124	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010 , 51, 73-80	11.2	275
123	Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. <i>Hepatology</i> , 2010 , 51, 1127-36 ^{11.2}		93
122	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010 , 52, 472-9	11.2	217
121	Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 172-9	4	84
120	Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4129-40	15.9	168
119	Hepatology (I) 2010 , 500-546		
118	Evaluation of angiotensinogen c.1-44G>A and p.M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies. <i>Genetic Testing and Molecular Biomarkers</i> , 2009 , 13, 407-14	1.6	2
117	Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 398-404	5.9	8
116	The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. <i>Journal of Infectious Diseases</i> , 2009 , 200, 1397-401	7	54
115	The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. <i>Hepatology</i> , 2009 , 49, 775-80	11.2	38
114	Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. <i>Hepatology</i> , 2009 , 50, 369-77	11.2	43
113	Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. <i>Journal of Clinical Immunology</i> , 2009 , 29, 620-8	5.7	17

112	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. <i>Nature Genetics</i> , 2009 , 41, 1100-4	36.3	1636
111	Elevated concentrations of 15-deoxy-Delta ^{12,14} -prostaglandin J ₂ in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs. <i>Liver International</i> , 2009 , 29, 730-5	7.9	5
110	Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2009 , 9, 847-52	4.5	9
109	A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2009 , 50, 370-6	13.4	69
108	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , 2009 , 136, 1618-28.e2	13.3	197
107	Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. <i>Gastroenterology</i> , 2009 , 137, 390-1	13.3	34
106	Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. <i>Gastroenterology</i> , 2009 , 137, 309-19, 319.e1-3	13.3	124
105	No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2008 , 32, 959-65	3.7	14
104	Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 584-92	2.4	12
103	Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. <i>Gastroenterology</i> , 2008 , 134, 1385-95	13.3	117
102	Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. <i>Lipids in Health and Disease</i> , 2008 , 7, 29	4.4	55
101	Tailored treatment for hepatitis C. <i>Clinics in Liver Disease</i> , 2008 , 12, 507-28, vii-viii	4.6	9
100	Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. <i>Human Immunology</i> , 2008 , 69, 861-6	2.3	23
99	The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2008 , 48, 208-15	13.4	58
98	The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2008 , 49, 688-94	13.4	75
97	Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2008 , 49, 339-45	13.4	9
96	Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease. <i>Cytokine</i> , 2008 , 42, 18-23	4	14
95	Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. <i>Nature Genetics</i> , 2008 , 40, 78-82	36.3	291

94	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. <i>Human Molecular Genetics</i> , 2008 , 17, 2967-77	5.6	144
93	Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV vaccination and evidence of Rift Valley Fever virus infection. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 3850-2	9.7	3
92	Role of tenofovir in the treatment of chronic HBV infection. <i>Future Virology</i> , 2008 , 3, 207-220	2.4	3
91	Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently normal alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin. <i>Liver International</i> , 2008 , 28, 61-71	7.9	10
90	Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. <i>Hepatology</i> , 2008 , 48, 1404-11	11.2	27
89	Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. <i>Antiviral Therapy</i> , 2008 , 13, 17-22	2.6	10
88	Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. <i>Hepatology</i> , 2007 , 45, 864-9	11.2	121
87	Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfecting patients. <i>Hepatology</i> , 2007 , 46, 1016-25	11.2	29
86	Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. <i>Hepatology</i> , 2007 , 46, 991-8	11.2	108
85	Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. <i>Hepatology</i> , 2007 , 46, 1155-65	11.2	57
84	Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. <i>Transplant International</i> , 2007 , 20, 771-8	3	12
83	Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2471-81	0.7	43
82	Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2724-31	0.7	14
81	Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. <i>New England Journal of Medicine</i> , 2007 , 357, 2227-36	59.2	364
80	Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C. <i>Transplantation</i> , 2007 , 84, 144-8	1.8	8
79	Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 947-51	2.2	41
78	Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). <i>Transplantation</i> , 2007 , 83, 351-3	1.8	39
77	Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 639-46	2.2	12

76	Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2007 , 46, 372-80	13.4	41
75	A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. <i>Journal of Hepatology</i> , 2007 , 47, 203-11	13.4	72
74	The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. <i>Journal of Hepatology</i> , 2007 , 47, 348-55	13.4	9
73	Benigne und maligne Neoplasien der Leber 2007 , 921-929		
72	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006 , 43, 250-6	11.2	195
71	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. <i>Hepatology</i> , 2006 , 44, 318-25	11.2	244
70	Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 644-51	4.5	29
69	Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. <i>Aids</i> , 2006 , 20, 2231-3	3.5	8
68	Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2006 , 12, 4491-8	12.9	57
67	Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. <i>Gastroenterology</i> , 2006 , 130, 1086-97	13.3	417
66	Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alpha-2B plus ribavirin. <i>Transplantation</i> , 2006 , 82, 43-7	1.8	74
65	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , 2006 , 20, 1951-4	3.5	58
64	Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. <i>Liver International</i> , 2006 , 26, 846-55	7.9	8
63	A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. <i>Nature Genetics</i> , 2006 , 38, 668-73	36.3	181
62	Computational methods for the design of effective therapies against drug resistant HIV strains. <i>Bioinformatics</i> , 2005 , 21, 3943-50	7.2	82
61	Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. <i>Gastroenterology</i> , 2005 , 129, 522-7	13.3	119
60	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , 2005 , 352, 2682-95	59.2	1226
59	Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 42, 793-8	13.4	149

58	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. <i>Journal of Hepatology</i> , 2005 , 43, 388-93	13.4	24
57	Peginterferon- α (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. <i>Gastroenterology</i> , 2005 , 129, 522-527	13.3	349
56	Prevention of hepatitis B recurrence after liver transplantation. <i>Transplantation</i> , 2005 , 80, S120-4	1.8	30
55	MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. <i>American Journal of Transplantation</i> , 2005 , 5, 406-11	8.7	56
54	New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2005 , 41, 1402-6	11.2	2
53	Reactivation of viral replication after replacement of tenofovir by adefovir. <i>Hepatology</i> , 2005 , 42, 239-40	11.2	15
52	Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. <i>Hepatology</i> , 2005 , 42, 724-31	11.2	200
51	Reply:. <i>Hepatology</i> , 2005 , 42, 1459-1460	11.2	0
50	Benigne und maligne Neoplasien der Leber 2005 , 837-844		
49	Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV-infected renal allograft recipients. <i>Clinical Transplantation</i> , 2004 , 18, 7-13	3.8	8
48	CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. <i>Journal of Molecular Medicine</i> , 2004 , 82, 64-9	5.5	28
47	Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. <i>Hepatology</i> , 2004 , 39, 1456-7; author reply 1457-8	11.2	34
46	Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. <i>Hepatology</i> , 2004 , 40, 327-34	11.2	31
45	Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. <i>Hepatology</i> , 2004 , 40, 1421-5	11.2	289
44	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004 , 40, 478-83	13.4	35
43	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004 , 41, 652-8	13.4	50
42	Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2004 , 41, 830-6	13.4	293
41	Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. <i>Transplantation</i> , 2004 , 77, 226-31	1.8	217

40	Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. <i>Otology and Neurotology</i> , 2004 , 25, 1020-6	2.6	63
39	Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. <i>Blood</i> , 2003 , 101, 259-64	2.2	117
38	Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. <i>Hepatology</i> , 2003 , 37, 600-9	11.2	223
37	Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. <i>Hepatology</i> , 2003 , 37, 1359-67	11.2	54
36	Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements. <i>Hepatology</i> , 2003 , 37, 1495-6; author reply 1496	11.2	6
35	Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. <i>Hepatology</i> , 2003 , 38, 1592; author reply 1592-3	11.2	27
34	Increased mortality after liver transplantation for hepatocellular carcinoma in hepatitis B-associated cirrhosis. <i>Transplant International</i> , 2003 , 16, 33-36	3	2
33	Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 2003 , 39, 245-52	13.4	35
32	Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. <i>Gastroenterology</i> , 2003 , 124, 586-7	13.3	37
31	Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. <i>Hepatology</i> , 2002 , 35, 1528-35	11.2	160
30	Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. <i>Hepatology</i> , 2002 , 36, 507-8	11.2	65
29	Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT. <i>Transplantation</i> , 2002 , 74, 792-8	1.8	14
28	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002 , 37, 843-7	13.4	25
27	Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial. <i>Journal of Hepatology</i> , 2002 , 36, 3	13.4	3
26	Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. <i>Journal of Medical Virology</i> , 2001 , 63, 128-134	19.7	26
25	Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. <i>Hepatology</i> , 2001 , 33, 1080-6	11.2	708
24	Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 976-82	4.5	31
23	Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. <i>Transplantation</i> , 2001 , 72, 1381-5	1.8	59

22	Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. <i>Liver</i> , 2000 , 20, 427-36		17
21	Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. <i>Transplant International</i> , 2000 , 13, 290-296	3	17
20	Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. <i>Hepatology</i> , 2000 , 32, 835-41	11.2	62
19	Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. <i>Journal of Infectious Diseases</i> , 2000 , 181, 432-41	7	99
18	Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. <i>Hepatology</i> , 2000 , 32, 1386-95	11.2	52
17	Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. <i>Transplant International</i> , 2000 , 13, 290-6	3	8
16	Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. <i>Transplantation</i> , 2000 , 69, 1739-42	1.8	14
15	Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. <i>Hepatology</i> , 1999 , 29, 245-9	11.2	36
14	Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors. <i>Journal of Medical Virology</i> , 1999 , 59, 117-21	19.7	20
13	Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. <i>Journal of Hepatology</i> , 1999 , 30, 1004-13	13.4	70
12	Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. <i>Hepatology</i> , 1998 , 27, 254-63	11.2	212
11	A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany. <i>Journal of Hepatology</i> , 1998 , 29, 375-84	13.4	40
10	Long-term efficacy of interferon alpha treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 1998 , 29, 511-2	13.4	
9	Hepatitis C virus (HCV)-infection and oral lichen planus. <i>Journal of Hepatology</i> , 1998 , 29, 1034-5	13.4	25
8	Quality control study on the performance of GB virus C/hepatitis G virus PCR. <i>Journal of Hepatology</i> , 1998 , 28, 978-84	13.4	13
7	Persistent hepatitis G virus infection after neonatal transfusion. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1998 , 26, 402-7	2.8	12
6	Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation. <i>Transplantation</i> , 1998 , 66, 225-8	1.8	19
5	Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. <i>Journal of Hepatology</i> , 1997 , 26, 484-91	13.4	48

4	Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany. <i>Journal of Hepatology</i> , 1996 , 25, 385-9	13.4	54
3	Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfecting with hepatitis G virus. <i>Journal of Hepatology</i> , 1996 , 25, 763-8	13.4	53
2	GB virus C infection in patients with chronic hepatitis B and C before and after liver transplantation. <i>Transplantation</i> , 1996 , 62, 711-4	1.8	38
1	Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients74-83		